Imaging mass spectrometry methodologies for studying the metabolites of cancer metastasis

研究癌症转移代谢物的成像质谱方法

基本信息

  • 批准号:
    10393491
  • 负责人:
  • 金额:
    $ 36.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-05-01 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

High grade serous ovarian cancer (HGSC) is the most common and deadliest form of ovarian cancer. Emerging evidence indicates that these tumors arise in the fallopian tube epithelium (FTE), and thus their presence in the ovary represents the primary metastasis. Our preliminary data identified that xenografting in close proximity to the ovary contributes to the aggressiveness of the disease. After ovarian colonization, tumor cells invade the peritoneal organs, primarily the omentum. We hypothesize that the biological problem of primary and secondary HGSC metastasis is partially mediated by chemical communication between the cancer cells and the metastatic organ. Our proposal seeks to define metabolites and biomolecules that drive the metastasis of fallopian tube derived high grade serous cancers to the ovary and the omentum. To this end, our teams optimized a 3D co-culture of the ovary and fallopian tube derived tumor models and adapted this to imaging mass spectrometry technology to identify the metabolomics-driven communication that occurs during primary colonization of the ovary and during secondary metastasis to the omentum. Using this emerging technology, we identified several metabolites that enhanced high grade serous tumor migration, invasion, and adhesion to the ovary. The focus of Aim 1 is to uncover the mechanisms allowing FTE tumorigenic cells to hijack NE produced by the ovary to increase their ability to invade and adhere to the ovary during primary metastasis. Aim 1 will define the signaling pathways mediated by NE during invasion and adhesion to the ovary and then confirm the importance of NE in vivo using both murine and human cell models derived from FTE. The key adrenergic receptor will be deleted using CRISPR to confirm the importance of this pathway in metastasis. Tumor bearing models will be treated with beta adrenergic receptor antagonists in an attempt to translate these findings for a new strategy to block ovarian colonization. The focus of Aim 2 is on the identification and characterization of a newly identified protein that is secreted from tumorigenic fallopian tube cells and is responsible for the production of ovarian norepinephrine driving tumor cell invasion and adhesion. We will use proteomics to confirm the identity of the secreted protein, followed by genetic deletion of the protein from FTE models to study the role in ovarian colonization. Aim 3 will build upon our existing technology of 3D organ and tumor cell communication models and expand into secondary metastasis. We have now optimized our technology for co-culture of the omentum together with tumor cell models and have an inventory of metabolites, which are unique and did not include norepinephrine. Instead a novel metabolite found to be produced in significantly more abundance when tumor cells were grown with the omentum corresponded to folate, the ligand for the folic acid receptor that is overexpressed in the tumor cells. Taken together, our innovative experimental approach will yield new pathways and targets to mitigate primary metastasis of high grade serous cancer to the ovary.
高级别浆液性卵巢癌(HGSC)是最常见和最致命的卵巢癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joanna E Burdette其他文献

Recreating the female reproductive tract in vitro using iPSC technology in a linked microfluidics environment
  • DOI:
    10.1186/scrt374
  • 发表时间:
    2013-12-01
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Monica M Laronda;Joanna E Burdette;J Julie Kim;Teresa K Woodruff
  • 通讯作者:
    Teresa K Woodruff

Joanna E Burdette的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joanna E Burdette', 18)}}的其他基金

Development of quantitative mass spectrometry assays and imaging for cancer metastasis
开发癌症转移的定量质谱分析和成像
  • 批准号:
    10533035
  • 财政年份:
    2020
  • 资助金额:
    $ 36.05万
  • 项目类别:
IRACDA at University of Illinois at Chicago
伊利诺伊大学芝加哥分校 IRACDA
  • 批准号:
    10055916
  • 财政年份:
    2020
  • 资助金额:
    $ 36.05万
  • 项目类别:
IRACDA at University of Illinois at Chicago
伊利诺伊大学芝加哥分校 IRACDA
  • 批准号:
    10460287
  • 财政年份:
    2020
  • 资助金额:
    $ 36.05万
  • 项目类别:
Imaging mass spectrometry methodologies for studying the metabolites of cancer metastasis
研究癌症转移代谢物的成像质谱方法
  • 批准号:
    10737811
  • 财政年份:
    2020
  • 资助金额:
    $ 36.05万
  • 项目类别:
IRACDA at University of Illinois at Chicago
伊利诺伊大学芝加哥分校 IRACDA
  • 批准号:
    10672429
  • 财政年份:
    2020
  • 资助金额:
    $ 36.05万
  • 项目类别:
Imaging mass spectrometry methodologies for studying the metabolites of cancer metastasis
研究癌症转移代谢物的成像质谱方法
  • 批准号:
    10622483
  • 财政年份:
    2020
  • 资助金额:
    $ 36.05万
  • 项目类别:
Dynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer
高级别浆液性卵巢癌中卵巢-输卵管轴的动态相互作用
  • 批准号:
    10190857
  • 财政年份:
    2019
  • 资助金额:
    $ 36.05万
  • 项目类别:
Dynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer
高级别浆液性卵巢癌中卵巢-输卵管轴的动态相互作用
  • 批准号:
    10667563
  • 财政年份:
    2019
  • 资助金额:
    $ 36.05万
  • 项目类别:
Microfluidic Models of Ovarian Cancer Preneoplastic Lesions
卵巢癌癌前病变的微流体模型
  • 批准号:
    10062680
  • 财政年份:
    2019
  • 资助金额:
    $ 36.05万
  • 项目类别:
Dynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer
高级别浆液性卵巢癌中卵巢-输卵管轴的动态相互作用
  • 批准号:
    10425372
  • 财政年份:
    2019
  • 资助金额:
    $ 36.05万
  • 项目类别:

相似海外基金

How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y004841/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.05万
  • 项目类别:
    Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
  • 批准号:
    BB/Y001427/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.05万
  • 项目类别:
    Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y005414/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.05万
  • 项目类别:
    Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
  • 批准号:
    10669829
  • 财政年份:
    2023
  • 资助金额:
    $ 36.05万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10587090
  • 财政年份:
    2023
  • 资助金额:
    $ 36.05万
  • 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
  • 批准号:
    10821599
  • 财政年份:
    2023
  • 资助金额:
    $ 36.05万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10841832
  • 财政年份:
    2023
  • 资助金额:
    $ 36.05万
  • 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
  • 批准号:
    10532480
  • 财政年份:
    2022
  • 资助金额:
    $ 36.05万
  • 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
  • 批准号:
    10741261
  • 财政年份:
    2022
  • 资助金额:
    $ 36.05万
  • 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
  • 批准号:
    10674894
  • 财政年份:
    2022
  • 资助金额:
    $ 36.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了